Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. more
Time Frame | FBIOP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.71% | -3.35% | -2.97% |
1-Month Return | 30.59% | -3.49% | -0.66% |
3-Month Return | 20.43% | -12.6% | 2.71% |
6-Month Return | -57.73% | -6.91% | 7.21% |
1-Year Return | -42.4% | 1.19% | 23.04% |
3-Year Return | -74.34% | -0.21% | 28.43% |
5-Year Return | -66.96% | 33.09% | 82.88% |
10-Year Return | -72.16% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 36.63M | 45.60M | 68.79M | 75.74M | 84.51M | [{"date":"2019-12-31","value":43.34,"profit":true},{"date":"2020-12-31","value":53.96,"profit":true},{"date":"2021-12-31","value":81.4,"profit":true},{"date":"2022-12-31","value":89.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 10.53M | 14.59M | 32.08M | 30.77M | 26.66M | [{"date":"2019-12-31","value":32.83,"profit":true},{"date":"2020-12-31","value":45.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.92,"profit":true},{"date":"2023-12-31","value":83.09,"profit":true}] |
Gross Profit | 26.10M | 31.00M | 36.71M | 44.97M | 57.85M | [{"date":"2019-12-31","value":45.11,"profit":true},{"date":"2020-12-31","value":53.59,"profit":true},{"date":"2021-12-31","value":63.45,"profit":true},{"date":"2022-12-31","value":77.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 71.25% | 67.99% | 53.36% | 59.37% | 68.45% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.44,"profit":true},{"date":"2021-12-31","value":74.89,"profit":true},{"date":"2022-12-31","value":83.33,"profit":true},{"date":"2023-12-31","value":96.08,"profit":true}] |
Operating Expenses | 136.92M | 125.28M | 215.71M | 247.23M | 200.19M | [{"date":"2019-12-31","value":55.38,"profit":true},{"date":"2020-12-31","value":50.67,"profit":true},{"date":"2021-12-31","value":87.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.98,"profit":true}] |
Operating Income | (110.82M) | (94.27M) | (179.00M) | (202.26M) | (142.34M) | [{"date":"2019-12-31","value":-11081900000,"profit":false},{"date":"2020-12-31","value":-9427000000,"profit":false},{"date":"2021-12-31","value":-17900100000,"profit":false},{"date":"2022-12-31","value":-20226000000,"profit":false},{"date":"2023-12-31","value":-14234200000,"profit":false}] |
Total Non-Operating Income/Expense | (131.00K) | (22.39M) | 9.53M | (22.14M) | (26.31M) | [{"date":"2019-12-31","value":-1.37,"profit":false},{"date":"2020-12-31","value":-234.94,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-232.39,"profit":false},{"date":"2023-12-31","value":-276.09,"profit":false}] |
Pre-Tax Income | (101.66M) | (102.85M) | (164.35M) | (213.46M) | (153.63M) | [{"date":"2019-12-31","value":-10166000000,"profit":false},{"date":"2020-12-31","value":-10284900000,"profit":false},{"date":"2021-12-31","value":-16435300000,"profit":false},{"date":"2022-12-31","value":-21346400000,"profit":false},{"date":"2023-12-31","value":-15363300000,"profit":false}] |
Income Taxes | (49.85M) | 136.00K | 473.00K | 449.00K | 521.00K | [{"date":"2019-12-31","value":-9568.33,"profit":false},{"date":"2020-12-31","value":26.1,"profit":true},{"date":"2021-12-31","value":90.79,"profit":true},{"date":"2022-12-31","value":86.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (51.81M) | (102.98M) | (164.83M) | (213.91M) | (154.15M) | [{"date":"2019-12-31","value":-5180900000,"profit":false},{"date":"2020-12-31","value":-10298500000,"profit":false},{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-15415400000,"profit":false}] |
Income From Continuous Operations | (101.66M) | (102.98M) | (164.83M) | (213.91M) | (182.62M) | [{"date":"2019-12-31","value":-10166000000,"profit":false},{"date":"2020-12-31","value":-10298500000,"profit":false},{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-18261500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (51.81M) | (102.98M) | (164.83M) | (213.91M) | (60.64M) | [{"date":"2019-12-31","value":-5180900000,"profit":false},{"date":"2020-12-31","value":-10298500000,"profit":false},{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-6063700000,"profit":false}] |
EPS (Diluted) | (0.71) | (0.56) | - | - | - | [{"date":"2019-12-31","value":-71,"profit":false},{"date":"2020-12-31","value":-55.54,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
FBIOP | |
---|---|
Cash Ratio | 0.84 |
Current Ratio | 1.23 |
Quick Ratio | 1.06 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
FBIOP | |
---|---|
ROA (LTM) | -36.41% |
ROE (LTM) | -1739.64% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
FBIOP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.17 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
FBIOP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.41 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Fortress Biotech Inc Pref Series A (FBIOP) share price today is $6.75
Yes, Indians can buy shares of Fortress Biotech Inc Pref Series A (FBIOP) on Vested. To buy Fortress Biotech Inc Pref Series A from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FBIOP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Fortress Biotech Inc Pref Series A (FBIOP) via the Vested app. You can start investing in Fortress Biotech Inc Pref Series A (FBIOP) with a minimum investment of $1.
You can invest in shares of Fortress Biotech Inc Pref Series A (FBIOP) via Vested in three simple steps:
The 52-week high price of Fortress Biotech Inc Pref Series A (FBIOP) is $17.47. The 52-week low price of Fortress Biotech Inc Pref Series A (FBIOP) is $4.86.
The price-to-earnings (P/E) ratio of Fortress Biotech Inc Pref Series A (FBIOP) is
The price-to-book (P/B) ratio of Fortress Biotech Inc Pref Series A (FBIOP) is 0.00
The dividend yield of Fortress Biotech Inc Pref Series A (FBIOP) is 45.96%
The market capitalization of Fortress Biotech Inc Pref Series A (FBIOP) is $34.19M
The stock symbol (or ticker) of Fortress Biotech Inc Pref Series A is FBIOP